Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hackner, K; Hütter, L; Flick, H; Grohs, M; Kastrati, K; Kiener, H; Lang, D; Mosheimer-Feistritzer, B; Prosch, H; Rath, E; Schindler, O; Moazedi-Fürst, F.
Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement.
Z Rheumatol. 2024;
Doi: 10.1007/s00393-023-01464-w
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Moazedi-Fürst Florentine
- Co-Autor*innen der Med Uni Graz
- Flick Holger
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major driver of premature mortality in patients with rheumatoid arthritis (RA). Detection of RA-ILD is crucial but requires awareness among the treating physicians. To date, however, there is no international recommendation concerning screening for ILD in RA patients. METHODS: After a systematic literature review, the modified Delphi technique in combination with the nominal group technique was used to provide a Delphi consensus statement elaborated by an expert panel of pneumonologists, rheumatologists, and a radiologist. Based on the available evidence, several clusters of questions were defined and discussed until consent was reached. RESULTS: A screening algorithm for ILD in patients with RA based on clinical signs, respiratory symptoms, and risk factors has been developed. Further, the recommendations address diagnostic tools for RA-ILD and the follow-up of RA patients qualifying for ILD screening.
- Find related publications in this database (Keywords)
- Autoimmune diseases
- Fibrosis
- Antifibrotic agents
- Risk factors
- Mass screening
- Autoimmunerkrankungen
- Fibrose
- Antifibrotika
- Risikofaktoren
- Massenscreening